Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lipocine Inc. (LPCN)

Lipocine Q3 net loss narrows to $0.7 million on $2.3 million revenue

Positive Impact 3 of 5 earnings Written later

Lipocine reported a third-quarter 2026 net loss of $0.7 million, or $0.08 per diluted share, down from a net loss of $3.2 million, or $0.59 per share, a year earlier. Revenue rose to $2.3 million from $115,000, driven by $2.1 million of license and collaboration revenue. Cash and marketable securities were $21.5 million at September 30, 2026, and about $28.5 million at November 4, 2026 (unaudited).

Key points

  • Q3 2026 net loss was $0.7 million ($0.08 per diluted share), compared with $3.2 million ($0.59 per share) in Q3 2025.
  • Q3 2026 total revenue was $2.3 million, including $2.1 million of license and collaboration revenue and $190,000 of TLANDO royalty revenue.
  • Cash, cash equivalents and marketable investment securities were $21.5 million at September 30, 2026, and about $28.5 million at November 4, 2026 (unaudited).
  • Nine-month net loss was $7.0 million ($0.90 per share), versus $7.3 million ($1.35 per share) a year earlier.

The filing

CompanyLipocine Inc. (LPCN)
Form8-K, current report
Filed with the SECNov 5, 2026, 9:35 AM ET
Accession number0001493152-26-050098

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.